Colorectal Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$4000
Buy Report View Sample

Published: November 30, 2020 Report Code: GDME1030EPD-ST

Select Item

Colorectal Cancer Diagnostic Tests are used for detection of CRC based on the detection and measurement of cancer-specific biomarker/antibody/antigen present in patient’s sample. GlobalData's Medical Devices sector report, “Colorectal Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Colorectal Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
The Colorectal Cancer Diagnostic Tests Pipeline Assessment report provides key information and data related to:
Extensive coverage of the Colorectal Cancer Diagnostic Tests under development
Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates
Reviews of major players involved in the pipeline product development.
Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and, the number of trials of the major Colorectal Cancer Diagnostic Tests pipeline products.
Review of Recent Developments in the segment / industry
The Colorectal Cancer Diagnostic Tests Pipeline Assessment report enables you to:
Access significant competitor information, analysis, and insights to improve your R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of Colorectal Cancer Diagnostic Tests under development
Formulate market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
The major companies covered in the “Colorectal Cancer Diagnostic Tests- Medical Devices Pipeline Assessment, 2020” report:
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
The GlobalData Differentiation

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

The data and analysis within this report are driven by GlobalData Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:

• 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2015 and forecast to 2025
• 6,700+ industry-leading analysis reports covering sector reports, medipoint reports, country analysis, expert insights and industry analysis (devices and procedures) reports
• 64,000+ medical equipment company profiles
• 5,600+ company profiles of medical equipment manufacturers in China and India
• 2,200+ company profiles of medical equipment manufacturers in Japan
• 1,200+ companies’ revenue splits and market shares
• 1,600+ quarterly and annual medical equipment company financials
• 850+ medical equipment company SWOTs
• 28,000+ pipeline product profiles
• 56,400+ marketed product profiles
• 47,000+ clinical trials
• 41,500+ trial investigators
• 7,000+ reports on companies with products in development
• 44,000+ deals in the medical equipment industry
• 1,100+ surgical and diagnostic procedures by therapy area
• 50+ key healthcare indicators by country
• 431,000+ Themes Content Items
• 600+ Influencers
• 1,900+ Analysts & Researchers
• 0.5m+ Community Members
• 141,000+ Macroeconomic Indicators
• 1,013,000+ City Indicators

For more information or to receive a free demonstration of the service, please visit:
https://medical.globaldata.com/home.aspx
Custom Requirements
Contact us to discuss the areas of your business where you need external input, and we will work with you to identify the strongest way forward to meet your needs.

Scope

– Extensive coverage of the Colorectal Cancer Diagnostic Tests under development

– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

– The report reviews the major players involved in the development of Colorectal Cancer Diagnostic Tests and list all their pipeline projects

– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

– The report provides key clinical trial data of ongoing trials specific to pipeline products

– Recent developments in the segment / industry

Reasons to Buy

The report enables you to:

– Formulate significant competitor information, analysis, and insights to improve R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of Colorectal Cancer Diagnostic Tests under development

– Develop market-entry and market expansion strategies

– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

– In-depth analysis of the product’s current stage of development, territory and estimated launch date

Abcodia Ltd
Almac Diagnostic Services Ltd
Ambergen Inc
Anixa Diagnostics Corporation
Applied Proteomics Inc
Arizona State University
Arrayit Corporation
ArtemixRx
Avant Diagnostics Inc
Bio Mark Ltd
Biocartis Group NV
Biodesix Inc
BioMarCare Technologies Ltd
BioMark Diagnostics Inc
BioMarker Strategies LLC
Biomoda Inc
Bioprognos SL
BioSystems International
Biotron Ltd
Calviri Inc
Castle Biosciences Inc
Catholic University of Leuven
Celcuity Inc
CellMax Life Inc
Cellmid Ltd
Ceres Nanosciences Inc
Cernostics Inc
ChemImage Corp
China Sky One Medical Inc
Columbia University
CS-Keys
Inc. (Inactive)
Di.V.A.L Toscana srl
DiagnoCure Inc. (Inactive)
Diazyme Laboratories Inc
DNAlytics SA
Duke University
EDP Biotech Corporation
EntreChem SL
Epigenomics AG
Eurobio Scientific SA
Eventus Diagnostics Inc (Inactive)
Exact Sciences Corp
Exiqon AS
Exosomics Siena SpA
Fina Biotech SL
Fox Chase Cancer Center
GenExosome Technologies Inc
GenomicTree Co Ltd
German Cancer Research Center
Ghent University
GlycoZym USA Inc
Health Discovery Corp
Hitachi Chemical Diagnostics Inc
Human Metabolome Technologies Inc
Ikonisys Inc
Institute of Molecular and Translational Medicine
InterGenetics Inc
Johns Hopkins University
King Abdullah University of Science and Technology
Kyo Diagnostics KK
Lab21 Ltd
Laboratorios Alpha San Ignacio Pharma S.L.
Leitat Technological Center
MabCure Inc
Master Diagnostica Sociedad Limitada
Matrix-Bio Inc
Max Delbruck Center for Molecular Medicine
Mayo Clinic
MDNA Life Sciences Inc
MDxHealth SA
Merrimack Pharmaceuticals Inc
Metabolon Inc
MetaStat Inc
Milagen Inc
Myriad Genetics Inc
Nanocytomics LLC
Norda ASA
Novel Bio-spectrum Technologies Inc (Inactive)
Nuclea Biotechnologies Inc. (Inactive)
Oncimmune (USA) LLC
OncoCyte Corp
Onconome
Inc. (Inactive)
Origin Sciences Ltd
Orion Genomics LLC
OTraces Inc
Oxford Cancer Biomarkers Ltd
Oxford Gene Technology Ltd
PleX Diagnostics Inc (Inactive)
Precision Biologics Inc
Prediction Sciences LLC (Inactive)
PreMD Inc (Inactive)
Prescient Medicine LLC
Protagen AG
Protein Alternatives SL
Qiagen NV
Quest Diagnostics Inc
Rabin Medical Center
Rhythm Biosciences Ltd
RISE Life Science Corp
Rosetta Genomics Ltd
Sanguine Diagnostics and Therapeutics Inc
Scienion AG
Seegene Inc
Shuwen Biotech Co Ltd
Sysmex Corp
Tel Aviv University
The Walter and Eliza Hall Institute of Medical Research
TheraDiag SA
Treos Bio Inc
Trinity College Dublin
Universal Diagnostics SL
University of Illinois at Chicago
University of Lyon
University of Michigan
University of Notre Dame
University of Texas MD Anderson Cancer Center
University of Turku
University of Washington
University of Wisconsin Madison
University of Zurich
US Biomarkers Inc
vall d hebron institut de Recerca
Vanderbilt University
Vastcon Inc
Viomics Inc.
VolitionRX Ltd
XEPTAGEN SpA

Table of Contents

1 Table of Contents 2

1.1 List of Tables 9

1.2 List of Figures 17

2 Introduction 18

2.1 Colorectal Cancer Overview 18

3 Products under Development 19

3.1 Colorectal Cancer – Pipeline Products by Stage of Development 19

3.2 Colorectal Cancer – Pipeline Products by Territory 20

3.3 Colorectal Cancer – Pipeline Products by Regulatory Path 21

3.4 Colorectal Cancer – Pipeline Products by Estimated Approval Date 22

3.5 Colorectal Cancer – Ongoing Clinical Trials 23

4 Colorectal Cancer – Pipeline Products under Development by Companies 24

4.1 Colorectal Cancer Companies – Pipeline Products by Stage of Development 24

4.2 Colorectal Cancer – Pipeline Products by Stage of Development 29

5 Colorectal Cancer Companies and Product Overview 33

5.1 Abcodia Ltd Company Overview 33

5.1.1 Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 33

5.2 Almac Diagnostic Services Ltd Company Overview 34

5.2.1 Almac Diagnostic Services Ltd Pipeline Products & Ongoing Clinical Trials Overview 34

5.3 Ambergen Inc Company Overview 35

5.3.1 Ambergen Inc Pipeline Products & Ongoing Clinical Trials Overview 35

5.4 Anixa Diagnostics Corporation Company Overview 36

5.4.1 Anixa Diagnostics Corporation Pipeline Products & Ongoing Clinical Trials Overview 36

5.5 Applied Proteomics Inc Company Overview 41

5.5.1 Applied Proteomics Inc Pipeline Products & Ongoing Clinical Trials Overview 41

5.6 Arizona State University Company Overview 42

5.6.1 Arizona State University Pipeline Products & Ongoing Clinical Trials Overview 42

5.7 Arrayit Corporation Company Overview 43

5.7.1 Arrayit Corporation Pipeline Products & Ongoing Clinical Trials Overview 43

5.8 ArtemixRx Company Overview 44

5.8.1 ArtemixRx Pipeline Products & Ongoing Clinical Trials Overview 44

5.9 Avant Diagnostics Inc Company Overview 45

5.9.1 Avant Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 45

5.10 Bio Mark Ltd Company Overview 46

5.10.1 Bio Mark Ltd Pipeline Products & Ongoing Clinical Trials Overview 46

5.11 Biocartis Group NV Company Overview 47

5.11.1 Biocartis Group NV Pipeline Products & Ongoing Clinical Trials Overview 47

5.12 Biodesix Inc Company Overview 49

5.12.1 Biodesix Inc Pipeline Products & Ongoing Clinical Trials Overview 49

5.13 BioMarCare Technologies Ltd Company Overview 50

5.13.1 BioMarCare Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 50

5.14 BioMark Diagnostics Inc Company Overview 51

5.14.1 BioMark Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 51

5.15 BioMarker Strategies LLC Company Overview 52

5.15.1 BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview 52

5.16 Biomoda Inc Company Overview 53

5.16.1 Biomoda Inc Pipeline Products & Ongoing Clinical Trials Overview 53

5.17 Bioprognos SL Company Overview 54

5.17.1 Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 54

5.18 BioSystems International Company Overview 55

5.18.1 BioSystems International Pipeline Products & Ongoing Clinical Trials Overview 55

5.19 Biotron Ltd Company Overview 56

5.19.1 Biotron Ltd Pipeline Products & Ongoing Clinical Trials Overview 56

5.20 Calviri Inc Company Overview 57

5.20.1 Calviri Inc Pipeline Products & Ongoing Clinical Trials Overview 57

5.21 Castle Biosciences Inc Company Overview 58

5.21.1 Castle Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 58

5.22 Catholic University of Leuven Company Overview 59

5.22.1 Catholic University of Leuven Pipeline Products & Ongoing Clinical Trials Overview 59

5.23 Celcuity Inc Company Overview 60

5.23.1 Celcuity Inc Pipeline Products & Ongoing Clinical Trials Overview 60

5.24 CellMax Life Inc Company Overview 61

5.24.1 CellMax Life Inc Pipeline Products & Ongoing Clinical Trials Overview 61

5.25 Cellmid Ltd Company Overview 62

5.25.1 Cellmid Ltd Pipeline Products & Ongoing Clinical Trials Overview 62

5.26 Ceres Nanosciences Inc Company Overview 64

5.26.1 Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 64

5.27 Cernostics Inc Company Overview 65

5.27.1 Cernostics Inc Pipeline Products & Ongoing Clinical Trials Overview 65

5.28 ChemImage Corp Company Overview 66

5.28.1 ChemImage Corp Pipeline Products & Ongoing Clinical Trials Overview 66

5.29 China Sky One Medical Inc Company Overview 67

5.29.1 China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 67

5.30 Columbia University Company Overview 68

5.30.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 68

5.31 CS-Keys, Inc. (Inactive) Company Overview 69

5.31.1 CS-Keys, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 69

5.32 Di.V.A.L Toscana srl Company Overview 70

5.32.1 Di.V.A.L Toscana srl Pipeline Products & Ongoing Clinical Trials Overview 70

5.33 DiagnoCure Inc. (Inactive) Company Overview 71

5.33.1 DiagnoCure Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 71

5.34 Diazyme Laboratories Inc Company Overview 73

5.34.1 Diazyme Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 73

5.35 DNAlytics SA Company Overview 74

5.35.1 DNAlytics SA Pipeline Products & Ongoing Clinical Trials Overview 74

5.36 Duke University Company Overview 75

5.36.1 Duke University Pipeline Products & Ongoing Clinical Trials Overview 75

5.37 EDP Biotech Corporation Company Overview 76

5.37.1 EDP Biotech Corporation Pipeline Products & Ongoing Clinical Trials Overview 76

5.38 EntreChem SL Company Overview 77

5.38.1 EntreChem SL Pipeline Products & Ongoing Clinical Trials Overview 77

5.39 Epigenomics AG Company Overview 78

5.39.1 Epigenomics AG Pipeline Products & Ongoing Clinical Trials Overview 78

5.40 Eurobio Scientific SA Company Overview 79

5.40.1 Eurobio Scientific SA Pipeline Products & Ongoing Clinical Trials Overview 79

5.41 Eventus Diagnostics Inc (Inactive) Company Overview 80

5.41.1 Eventus Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 80

5.42 Exact Sciences Corp Company Overview 81

5.42.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 81

5.43 Exiqon AS Company Overview 82

5.43.1 Exiqon AS Pipeline Products & Ongoing Clinical Trials Overview 82

5.44 Exosomics Siena SpA Company Overview 83

5.44.1 Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview 83

5.45 Fina Biotech SL Company Overview 84

5.45.1 Fina Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 84

5.46 Fox Chase Cancer Center Company Overview 85

5.46.1 Fox Chase Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 85

5.47 GenExosome Technologies Inc Company Overview 87

5.47.1 GenExosome Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 87

5.48 GenomicTree Co Ltd Company Overview 88

5.48.1 GenomicTree Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 88

5.49 German Cancer Research Center Company Overview 92

5.49.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 92

5.50 Ghent University Company Overview 94

5.50.1 Ghent University Pipeline Products & Ongoing Clinical Trials Overview 94

5.51 GlycoZym USA Inc Company Overview 95

5.51.1 GlycoZym USA Inc Pipeline Products & Ongoing Clinical Trials Overview 95

5.52 Health Discovery Corp Company Overview 96

5.52.1 Health Discovery Corp Pipeline Products & Ongoing Clinical Trials Overview 96

5.53 Hitachi Chemical Diagnostics Inc Company Overview 97

5.53.1 Hitachi Chemical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 97

5.54 Human Metabolome Technologies Inc Company Overview 98

5.54.1 Human Metabolome Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 98

5.55 Ikonisys Inc Company Overview 99

5.55.1 Ikonisys Inc Pipeline Products & Ongoing Clinical Trials Overview 99

5.56 Institute of Molecular and Translational Medicine Company Overview 100

5.56.1 Institute of Molecular and Translational Medicine Pipeline Products & Ongoing Clinical Trials Overview 100

5.57 InterGenetics Inc Company Overview 101

5.57.1 InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview 101

5.58 Johns Hopkins University Company Overview 102

5.58.1 Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 102

5.59 King Abdullah University of Science and Technology Company Overview 104

5.59.1 King Abdullah University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 104

5.60 Kyo Diagnostics KK Company Overview 105

5.60.1 Kyo Diagnostics KK Pipeline Products & Ongoing Clinical Trials Overview 105

5.61 Lab21 Ltd Company Overview 106

5.61.1 Lab21 Ltd Pipeline Products & Ongoing Clinical Trials Overview 106

5.62 Laboratorios Alpha San Ignacio Pharma S.L. Company Overview 107

5.62.1 Laboratorios Alpha San Ignacio Pharma S.L. Pipeline Products & Ongoing Clinical Trials Overview 107

5.63 Leitat Technological Center Company Overview 108

5.63.1 Leitat Technological Center Pipeline Products & Ongoing Clinical Trials Overview 108

5.64 MabCure Inc Company Overview 110

5.64.1 MabCure Inc Pipeline Products & Ongoing Clinical Trials Overview 110

5.65 Master Diagnostica Sociedad Limitada Company Overview 111

5.65.1 Master Diagnostica Sociedad Limitada Pipeline Products & Ongoing Clinical Trials Overview 111

5.66 Matrix-Bio Inc Company Overview 112

5.66.1 Matrix-Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 112

5.67 Max Delbruck Center for Molecular Medicine Company Overview 115

5.67.1 Max Delbruck Center for Molecular Medicine Pipeline Products & Ongoing Clinical Trials Overview 115

5.68 Mayo Clinic Company Overview 116

5.68.1 Mayo Clinic Pipeline Products & Ongoing Clinical Trials Overview 116

5.69 MDNA Life Sciences Inc Company Overview 117

5.69.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 117

5.70 MDxHealth SA Company Overview 118

5.70.1 MDxHealth SA Pipeline Products & Ongoing Clinical Trials Overview 118

5.71 Merrimack Pharmaceuticals Inc Company Overview 120

5.71.1 Merrimack Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 120

5.72 Metabolon Inc Company Overview 121

5.72.1 Metabolon Inc Pipeline Products & Ongoing Clinical Trials Overview 121

5.73 MetaStat Inc Company Overview 122

5.73.1 MetaStat Inc Pipeline Products & Ongoing Clinical Trials Overview 122

5.74 Milagen Inc Company Overview 123

5.74.1 Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 123

5.75 Myriad Genetics Inc Company Overview 124

5.75.1 Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 124

5.76 Nanocytomics LLC Company Overview 125

5.76.1 Nanocytomics LLC Pipeline Products & Ongoing Clinical Trials Overview 125

5.77 Norda ASA Company Overview 126

5.77.1 Norda ASA Pipeline Products & Ongoing Clinical Trials Overview 126

5.78 Novel Bio-spectrum Technologies Inc (Inactive) Company Overview 127

5.78.1 Novel Bio-spectrum Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 127

5.79 Nuclea Biotechnologies Inc. (Inactive) Company Overview 128

5.79.1 Nuclea Biotechnologies Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 128

5.80 Oncimmune (USA) LLC Company Overview 129

5.80.1 Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 129

5.81 OncoCyte Corp Company Overview 130

5.81.1 OncoCyte Corp Pipeline Products & Ongoing Clinical Trials Overview 130

5.82 Onconome, Inc. (Inactive) Company Overview 131

5.82.1 Onconome, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 131

5.83 Origin Sciences Ltd Company Overview 132

5.83.1 Origin Sciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 132

5.84 Orion Genomics LLC Company Overview 133

5.84.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 133

5.85 OTraces Inc Company Overview 134

5.85.1 OTraces Inc Pipeline Products & Ongoing Clinical Trials Overview 134

5.86 Oxford Cancer Biomarkers Ltd Company Overview 135

5.86.1 Oxford Cancer Biomarkers Ltd Pipeline Products & Ongoing Clinical Trials Overview 135

5.87 Oxford Gene Technology Ltd Company Overview 136

5.87.1 Oxford Gene Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 136

5.88 PleX Diagnostics Inc (Inactive) Company Overview 137

5.88.1 PleX Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 137

5.89 Precision Biologics Inc Company Overview 138

5.89.1 Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 138

5.90 Prediction Sciences LLC (Inactive) Company Overview 139

5.90.1 Prediction Sciences LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 139

5.91 PreMD Inc (Inactive) Company Overview 140

5.91.1 PreMD Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 140

5.92 Prescient Medicine LLC Company Overview 141

5.92.1 Prescient Medicine LLC Pipeline Products & Ongoing Clinical Trials Overview 141

5.93 Protagen AG Company Overview 142

5.93.1 Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 142

5.94 Protein Alternatives SL Company Overview 143

5.94.1 Protein Alternatives SL Pipeline Products & Ongoing Clinical Trials Overview 143

5.95 Qiagen NV Company Overview 144

5.95.1 Qiagen NV Pipeline Products & Ongoing Clinical Trials Overview 144

5.96 Quest Diagnostics Inc Company Overview 145

5.96.1 Quest Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 145

5.97 Rabin Medical Center Company Overview 146

5.97.1 Rabin Medical Center Pipeline Products & Ongoing Clinical Trials Overview 146

5.98 Rhythm Biosciences Ltd Company Overview 147

5.98.1 Rhythm Biosciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 147

5.99 RISE Life Science Corp Company Overview 150

5.99.1 RISE Life Science Corp Pipeline Products & Ongoing Clinical Trials Overview 150

5.100 Rosetta Genomics Ltd Company Overview 151

5.100.1 Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview 151

5.101 Sanguine Diagnostics and Therapeutics Inc Company Overview 152

5.101.1 Sanguine Diagnostics and Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 152

5.102 Scienion AG Company Overview 153

5.102.1 Scienion AG Pipeline Products & Ongoing Clinical Trials Overview 153

5.103 Seegene Inc Company Overview 154

5.103.1 Seegene Inc Pipeline Products & Ongoing Clinical Trials Overview 154

5.104 Shuwen Biotech Co Ltd Company Overview 155

5.104.1 Shuwen Biotech Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 155

5.105 Sysmex Corp Company Overview 156

5.105.1 Sysmex Corp Pipeline Products & Ongoing Clinical Trials Overview 156

5.106 Tel Aviv University Company Overview 157

5.106.1 Tel Aviv University Pipeline Products & Ongoing Clinical Trials Overview 157

5.107 The Walter and Eliza Hall Institute of Medical Research Company Overview 158

5.107.1 The Walter and Eliza Hall Institute of Medical Research Pipeline Products & Ongoing Clinical Trials Overview 158

5.108 TheraDiag SA Company Overview 159

5.108.1 TheraDiag SA Pipeline Products & Ongoing Clinical Trials Overview 159

5.109 Treos Bio Inc Company Overview 161

5.109.1 Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 161

5.110 Trinity College Dublin Company Overview 162

5.110.1 Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview 162

5.111 Universal Diagnostics SL Company Overview 163

5.111.1 Universal Diagnostics SL Pipeline Products & Ongoing Clinical Trials Overview 163

5.112 University of Illinois at Chicago Company Overview 164

5.112.1 University of Illinois at Chicago Pipeline Products & Ongoing Clinical Trials Overview 164

5.113 University of Lyon Company Overview 165

5.113.1 University of Lyon Pipeline Products & Ongoing Clinical Trials Overview 165

5.114 University of Michigan Company Overview 166

5.114.1 University of Michigan Pipeline Products & Ongoing Clinical Trials Overview 166

5.115 University of Notre Dame Company Overview 167

5.115.1 University of Notre Dame Pipeline Products & Ongoing Clinical Trials Overview 167

5.116 University of Texas MD Anderson Cancer Center Company Overview 168

5.116.1 University of Texas MD Anderson Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 168

5.117 University of Turku Company Overview 170

5.117.1 University of Turku Pipeline Products & Ongoing Clinical Trials Overview 170

5.118 University of Washington Company Overview 171

5.118.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 171

5.119 University of Wisconsin Madison Company Overview 172

5.119.1 University of Wisconsin Madison Pipeline Products & Ongoing Clinical Trials Overview 172

5.120 University of Zurich Company Overview 173

5.120.1 University of Zurich Pipeline Products & Ongoing Clinical Trials Overview 173

5.121 US Biomarkers Inc Company Overview 174

5.121.1 US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 174

5.122 vall d hebron institut de Recerca Company Overview 175

5.122.1 vall d hebron institut de Recerca Pipeline Products & Ongoing Clinical Trials Overview 175

5.123 Vanderbilt University Company Overview 177

5.123.1 Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview 177

5.124 Vastcon Inc Company Overview 179

5.124.1 Vastcon Inc Pipeline Products & Ongoing Clinical Trials Overview 179

5.125 Viomics Inc. Company Overview 180

5.125.1 Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 180

5.126 VolitionRX Ltd Company Overview 181

5.126.1 VolitionRX Ltd Pipeline Products & Ongoing Clinical Trials Overview 181

5.127 XEPTAGEN SpA Company Overview 187

5.127.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 187

6 Colorectal Cancer- Recent Developments 188

6.1 Jun 23, 2020: Vall d'Hebron identifies a prognostic marker in rectal cancer based on the intestinal microbiome 188

6.2 May 04, 2020: StageZero Life Sciences announces enhanced relationship with Phleb-Finders 189

6.3 Apr 29, 2020: Cancer testing and diagnosis suffers sharp downturn, finds Diaceutics 190

6.4 Apr 15, 2020: Indivumed launches global oncology alliance for personalized medicine ("Onco AI-Med") 191

6.5 Apr 03, 2020: StageZero Life Sciences announces publication of abstract at american society of clinical oncology 192

6.6 Apr 03, 2020: NeoGenomics integrates HALO from Indica Labs 192

6.7 Apr 01, 2020: Genetic Technologies announces market update on sales, early test results and launch of consumer initiated testing 193

6.8 Mar 17, 2020: Olympus supports national colorectal cancer awareness month 194

6.9 Mar 12, 2020: Lineage Cell Therapeutics reports fourth quarter and full year 2019 financial results and provides business update 195

6.10 Mar 06, 2020: 2cureX is accelerating the commercialization of IndiTreat by signing two distributor agreements to prepare for launch in second half of 2020 199

6.11 Mar 05, 2020: Biocartis announces new immuno-oncology project with Bristol-Myers Squibb aimed at registration of Idylla MSI test in China 200

6.12 Mar 05, 2020: Biocartis Group: Biocartis announces 2019 results and 2020 outlook 200

6.13 Mar 04, 2020: Immunoscore in the WHO Classification of Digestive System Tumours 207

6.14 Feb 29, 2020: MGI's response to Illumina's complaint 207

6.15 Feb 26, 2020: MDxHealth reports financial year 2019 results and provides outlook for 2020 208

6.16 Feb 26, 2020: bioMerieux – 2019 financial results 210

6.17 Feb 26, 2020: Mayo Clinic reports 'remarkable growth' in 2019 213

6.18 Feb 25, 2020: TCS digitally transforms Qiagen’s global research platform to improve user experience with new digital capabilities 214

6.19 Feb 19, 2020: Biohit Group financial statement release 2019 214

6.20 Feb 11, 2020: Exact Sciences announces fourth-quarter 2019 results 219

6.21 Feb 10, 2020: PRA Health Sciences reports fourth quarter and full year 2019 results and provides first quarter and full year 2020 guidance 220

6.22 Feb 06, 2020: Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors 222

6.23 Feb 06, 2020: Myriad announces leadership transition 222

6.24 Feb 06, 2020: Myriad Genetics reports fiscal second-quarter 2020 financial results 223

6.25 Feb 06, 2020: Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors 225

6.26 Jan 30, 2020: Update on 2cureX’s clinical trial in metastatic colorectal cancer: 75% of the scheduled patients have been treated in accordance with the IndiTreat test 225

6.27 Jan 30, 2020: Theradiag reports 2019 revenue of €9.6 million, Up

8.3% 226

6.28 Jan 30, 2020: OGT launches breakthrough NGS panel for constitutional cytogenetics 228

6.29 Jan 27, 2020: Biocartis announces resignation CFO 229

6.30 Jan 21, 2020: Biomark’s scientific advisor named Dean of the Schulich School of Medicine and Dentistry 229

6.31 Jan 14, 2020: Dr. Thomas P. Slavin named Senior Vice President of Medical Affairs for Myriad Oncology 229

6.32 Jan 12, 2020: Exact Sciences announces preliminary fourth quarter 2019 results 230

6.33 Jan 09, 2020: Biocartis meets 2019 key business objectives 231

6.34 Jan 07, 2020: Jant Pharmacal is awarded contract from Vizient 232

6.35 Jan 02, 2020: Lineage Cell Therapeutics conducts sale of shares in oncocyte 232

6.36 Dec 31, 2019: Biomark announces appointment of Scientific and Medical Advisors, grant of stock options and changes in Board Of Directors 233

6.37 Dec 29, 2019: Illumina reports financial results for fourth quarter and fiscal year 2019 233

6.38 Dec 23, 2019: Mayo Clinic names chief digital officer to lead transformative digital strategy, create Center for Digital Health 235

6.39 Dec 19, 2019: Biomark Diagnostics reviews 2019 and outlines plans for 2020 235

6.40 Dec 18, 2019: A new biomarker for colorectal cancer 239

6.41 Dec 13, 2019: Hospitals and cancer care givers can now offer the IndiTreat test to their cancer patients. 239

6.42 Dec 13, 2019: 2cureX presented progression in the IndiTreat immuno-oncology assay development at the ESMO Immuno-Oncology Congress in Geneva 239

6.43 Dec 13, 2019: NetScientific announces changes to its Board of Directors 240

6.44 Dec 10, 2019: 2cureX launches IndiTreat.com as an important component of 2cureX’s preparation for the product launch of IndiTreat in 2020 241

6.45 Dec 03, 2019: Dr. John Halamka named president of Mayo Clinic Platform 241

6.46 Nov 21, 2019: Development of colorectal cancer detection kit 242

6.47 Nov 21, 2019: Pacific Edge announces FY20 results and capital raising 243

6.48 Nov 19, 2019: Epigenomics reports financial results for the first nine months 2019 246

6.49 Nov 15, 2019: StageZero Life Sciences announces Q3 2019 progress update 247

6.50 Nov 14, 2019: Biocartis Q3 2019 business update 248

6.51 Nov 14, 2019: BioIQ conducts one millionth colorectal cancer screening 251

6.52 Nov 14, 2019: Biocartisb Q3 2019 business update 251

6.53 Nov 12, 2019: Lineage Cell Therapeutics reports third quarter 2019 financial results and provides business update 253

6.54 Nov 12, 2019: VolitionRx announces third quarter 2019 financial results and business update 256

6.55 Nov 12, 2019: Vermillion reports third quarter 2019 financial results 258

6.56 Nov 12, 2019: OGT continues move into molecular diagnostics markets 259

7 Appendix 261

7.1 Methodology 261

7.2 About GlobalData 265

7.3 Contact Us 265

7.4 Disclaimer 265

Frequently asked questions

Colorectal Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020 thematic reports
Currency USD
$4,000

Can be used by individual purchaser only

Most Popular
$8,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$12,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Colorectal Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more In Vitro Diagnostics reports
Medical Devices
India Surgical Energy Instruments Market Size (Value, Volume, ASP) by…
$500 | November 2020
Medical Devices
Japan Surgical Energy Instruments Market Size (Value, Volume, ASP) by…
$500 | November 2020
Medical Devices
New Zealand Surgical Energy Instruments Market Size (Value, Volume, ASP)…
$500 | November 2020
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Colorectal Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020 in real time.

  • Access a live Colorectal Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more